[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521216":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":37,"centralContacts":41,"locations":50,"responsibleParty":67,"collaborators":27,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":27,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":27,"enrollmentInfo":79,"targetDuration":27,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":27,"overallStatus":52,"whyStopped":27,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Missouri-Columbia","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Propanolol and MRI","EXPERIMENTAL","Participants will receive propranolol via oral capsule. The drug dosage will be titrated slowly to ensure the drug is tolerated well.",[13,14],"Drug: Propranolol","Device: Magnetic Resonance Imaging (MRI)",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo and MRI","PLACEBO_COMPARATOR","Participants will receive placebo via oral capsule.",[14,20],"Drug: Placebo",[22,28,33],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Propranolol","Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.",[9],null,{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":27},"DEVICE","Magnetic Resonance Imaging (MRI)","Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.",[16,9],{"type":23,"name":34,"description":35,"armGroupLabels":36,"otherNames":27},"Placebo","Placebo will be given on the same schedule as the propranolol regime.",[16],[38],{"name":39,"affiliation":5,"role":40},"David Beversdorf, MD","PRINCIPAL_INVESTIGATOR",[42,46],{"name":39,"role":43,"phone":44,"phoneExt":27,"email":45},"CONTACT","573-882-6081","beversdorfd@health.missouri.edu",{"name":47,"role":43,"phone":48,"phoneExt":27,"email":49},"Jessica Call","573-882-0515","jccfx@health.missouri.edu",[51],{"facility":5,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Columbia","Missouri","65212","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-92.33407,38.95171,{"lat":62,"lon":61},[65,66],{"name":39,"role":43,"phone":44,"phoneExt":27,"email":45},{"name":47,"role":43,"phone":48,"phoneExt":27,"email":49},{"type":40,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"David Beversdorf","Professor, Department of Radiology & Thompson Center for Autism & Neurodevelopmental Disorders, University of Missouri-Columbia","100521216","early-phase-1-propranolol-in-primary-progressive-aphasia-100521216",false,"NCT06066710","Propranolol in Primary Progressive Aphasia","Trial of Propranolol in Older Adults with Primary Progressive Aphasia","Inclusion Criteria:\n\n* 1\\. Age: 50 and older\n* 2\\. Primary Progressive Aphasia diagnosis\n* 3\\. Native English speaker\n\nExclusion Criteria:\n\n* 1\\. Unable to provide consent\n* 2\\. Taking alpha 2 agonists (clonidine and guanfacine)\n* 3\\. Other major psychological or neurological diagnosis\n* 4\\. Major head trauma that contributed to their condition\n* 5\\. Allergic reaction to adhesives\n* 6\\. Uncorrected vision\u002Fhearing impairments\n* 7\\. Diabetes\n* 8\\. Reactive airway disease\n* 9\\. Untreated hypothyroidism\n* 10\\. Bradyarrhythmia\n* 11\\. Unexplained syncope\n* 12\\. Pregnancy (assessed verbally on the days of MR imaging)\n* 13\\. Drugs that interact with propranolol, such as alpha 2 agonists\n* 14\\. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.","ALL","50 Years",{"count":80,"type":81},30,"ESTIMATED","INTERVENTIONAL",[84],"EARLY_PHASE1","The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure.\n\nThis research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.",[87],"Aphasia, Primary Progressive","2025-03-24",{"date":90,"type":91},"2025-03-28","ACTUAL",{"date":93,"type":91},"2025-01-13",{"date":95,"type":81},"2027-12",{"name":5,"class":6},1]